Northpond Ventures
VC Fund
Bethesda, United States
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
- Total investments:
- 151
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Northpond Ventures invests in
Stages Northpond Ventures invests in
Countries Northpond Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $13M–$65M
- Series B
- $15M–$95M
- Series C
- $23M–$85M
Investment Focus
Industry
- Biotechnology 53 (35%)
- Health Care 37 (25%)
- Life Science 22 (15%)
- Health Diagnostics 19 (13%)
- Therapeutics 18 (12%)
Stage
- Series A 39 (26%)
- Series B 26 (17%)
- Series C 19 (13%)
- Series D 8 (5%)
- Venture - Series Unknown 6 (4%)
Country
- United States 63 (42%)
- United Kingdom 5 (3%)
- Canada 2 (1%)
- Germany 1 (1%)
- Australia 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam Wieschhaus
Director
|
Director | Total investments: 8 | Find email | |
Andrew Lee
Managing Director
|
Managing Director | Total investments: 6 | Find email | |
|
Connor McDermott
Vice President
|
Vice President | Total investments: 1 | Find email | |
Karthik Bolisetty
Senior Associate
|
Senior Associate | Total investments: 0 | Find email | |
Michael Rubin
Founder & CEO
|
Founder & CEO | Total investments: 37 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Faro AI
|
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value. | $37.3M / Series B / Aug 26, 2026 | |
Mestag Therapeutics
|
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology. | $40M / Venture - Series Unknown / Mar 17, 2026 | |
VieCure
|
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time. They codify the world’s premier cancer information in an engine that considers each patient’s unique needs and creates the most personalized comprehensive care plan. By accessing our evidence-based knowledge, oncologistscan create actionable cancer patient-specific personalized treatment plans that comply with nationally-accepted standards and the latest genomic-based guidelines. | $43M / Venture - Series Unknown / Jan 12, 2026 | |
|
VieCure
|
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time. They codify the world’s premier cancer information in an engine that considers each patient’s unique needs and creates the most personalized comprehensive care plan. By accessing our evidence-based knowledge, oncologistscan create actionable cancer patient-specific personalized treatment plans that comply with nationally-accepted standards and the latest genomic-based guidelines. | $43M / Venture - Series Unknown / Jan 12, 2026 | |
Vizgen
|
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. | $48M / Series E / Jan 08, 2026 | |
|
Vizgen
|
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. | $48M / Series E / Jan 08, 2026 | |
Elephas
|
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodalmicroscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development. | $40M / Venture - Series Unknown / Nov 06, 2025 | |
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
Outcomes4Me
|
Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $21M / Series A / May 29, 2025 | |
|
Outcomes4Me
|
Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $21M / Series A / May 29, 2025 | |
| See all 151 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Northpond Ventures invest in?
Northpond Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 151 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Northpond Ventures's check size?
Northpond Ventures typically joins rounds of $13M–$65M at Series A, $15M–$95M at Series B and $23M–$85M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Northpond Ventures participates in.
How do I contact Northpond Ventures?
Public channels for Northpond Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Northpond Ventures?
The team at Northpond Ventures includes Adam Wieschhaus (Director), Andrew Lee (Managing Director) and Connor McDermott (Vice President), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
